Accelerating global innovation to address antibacterial resistance: introducing CARB-X

A global response to the chronic shortfall in antibiotic innovation is urgently needed to combat antimicrobial resistance. Here, we introduce CARB-X, a new global public–private partnership that will invest more than US$350 million in the next 5 years to accelerate the progression of a diverse portf...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature reviews. Drug discovery 2016-09, Vol.15 (9), p.589-590
Hauptverfasser:	Outterson, Kevin, Rex, John H., Jinks, Tim, Jackson, Peter, Hallinan, John, Karp, Steve, Hung, Deborah T., Franceschi, Francois, Merkeley, Tyler, Houchens, Christopher, Dixon, Dennis M., Kurilla, Michael G., Aurigemma, Rosemarie, Larsen, Joseph
Format:	Artikel
Sprache:	eng
Schlagworte:	631/154/1435 631/154/2426 692/308/153 692/699/255 Aims and objectives Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Bacterial Infections - drug therapy Bacterial Infections - microbiology Biomedical and Life Sciences Biomedical Research - economics Biomedical Research - organization & administration Biomedicine Biotechnology Cancer Research Clinical Trials as Topic comment Drug Resistance, Bacterial Forecasts and trends Humans Medicinal Chemistry Microbial drug resistance Molecular Medicine Pharmaceutical research Pharmacology/Toxicology Prevention Public-private sector cooperation Public-Private Sector Partnerships
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A global response to the chronic shortfall in antibiotic innovation is urgently needed to combat antimicrobial resistance. Here, we introduce CARB-X, a new global public–private partnership that will invest more than US$350 million in the next 5 years to accelerate the progression of a diverse portfolio of innovative antibacterial products into clinical trials. A global response to the chronic shortfall in antibiotic innovation is urgently needed to combat antimicrobial resistance. Here, we introduce CARB-X, a new global public–private partnership that will invest more than US$350 million in the next 5 years to accelerate the progression of a diverse portfolio of innovative antibacterial products into clinical trials.
ISSN:	1474-1776 1474-1784
DOI:	10.1038/nrd.2016.155